Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Everolimus (Primary) ; Ribociclib (Primary)
- Indications Leiomyosarcoma; Liposarcoma
- Focus Therapeutic Use
- 12 Jul 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 12 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Dec 2024.
- 22 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.